Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

被引：2
|
作者：
Vij, Ravi [1 ]
Savona, Michael [2 ]
Siegel, David S. [3 ]
Kaufman, Jonathan L. [4 ]
Badros, Ashraf [5 ]
Ghobrial, Irene M. [6 ]
Paner, Agne [7 ]
Jagannath, Sundar [8 ]
Jakubowiak, Andrzej [9 ]
Mikhael, Joseph R. [10 ]
Kapoor, Prashant [11 ]
Neuman, Linda L. [12 ]
Lee, Ju RueyJiuan [13 ]
Berdeja, Jesus G. [14 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[3] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Univ Maryland, Baltimore, MD 21201 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[8] Mt Sinai Hosp, New York, NY 10029 USA
[9] Univ Chicago Med, Chicago, IL USA
[10] Mayo Clin Arizona, Scottsdale, AZ USA
[11] Mayo Clin, Rochester, MN USA
[12] Onyx Pharmaceut Inc, Redwood City, CA USA
[13] Onyx Pharmaceut Inc, San Francisco, CA USA
[14] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.
    Puzanov, Igor
    LoRusso, Patricia
    Papadopoulos, Kyriakos P.
    Chen, Christopher T.
    LeBruchec, Yvan
    He, Xiaomin
    Cousin, Thierry
    Havenith, Karin
    Boni, Joseph
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [34] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Twelves, Chris
    Anthoney, Alan
    Savulsky, Claudio, I
    Guo, Matthew
    Reyderman, Larisa
    Cresti, Nicola
    Semiglazov, Vladimir
    Timcheva, Constanta
    Zubairi, Ishtiaq
    Morrison, Rosemary
    Plummer, Ruth
    Evans, T. R. Jeffry
    BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 579 - 586
  • [35] Phase Ⅱ open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
    Yun Leng
    Lugui Qiu
    Jian Hou
    Yaozhong Zhao
    Xuejun Zhang
    Shifang Yang
    Hao Xi
    Zhongxia Huang
    Ling Pan
    Wenming Chen
    Chinese Journal of Cancer, 2016, 35 (12) : 699 - 705
  • [36] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Chris Twelves
    Alan Anthoney
    Claudio I. Savulsky
    Matthew Guo
    Larisa Reyderman
    Nicola Cresti
    Vladimir Semiglazov
    Constanta Timcheva
    Ishtiaq Zubairi
    Rosemary Morrison
    Ruth Plummer
    T. R. Jeffry Evans
    British Journal of Cancer, 2019, 120 : 579 - 586
  • [37] SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)
    Dimopoulos, M.
    Trotman, J.
    Tedeschi, A.
    Matous, J. V.
    Macdonald, D.
    Tam, C.
    Tournilhac, O.
    Ma, S.
    Oriol, A.
    Heffner, L.
    Shustik, C.
    Garcia-Sanz, R.
    Cornell, R. F.
    Fernandez de Larrea, C.
    Castillo, J. J.
    Granell, M.
    Kyrtsonis, M. C.
    Leblond, V.
    Symeonidis, A.
    Singh, P.
    Li, J.
    Graef, T.
    Bilotti, E.
    Treon, S.
    Buske, C.
    HAEMATOLOGICA, 2016, 101 : 256 - 257
  • [38] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
    Chari, Ajai
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Nahi, Hareth
    Tang, Jie
    Hellemans, Peter
    Tromp, Brenda
    Clemens, Pamela L.
    Farnsworth, Andrew
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2018, 132
  • [39] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [40] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
12345